Tumor necrosis factor a
a b s t r a c t
Pharmacological interference with vacuolar-type H(+)-ATPase (V-ATPase), a proton-translocating enzyme involved in protein transport and pH regulation of cell organelles, is considered a potential strategy for cancer therapy. Macrophages are critically involved in tumor progression and may occur as protumoral M2 phenotype, whereas classically-activated M1 can inhibit tumor development for example by releasing tumor-suppressing molecules, including tumor necrosis factor (TNF)a. Here, we show that targeting V-ATPase by selective inhibitors such as archazolid upregulates the expression and secretion of TNFa in lipopolysaccharide (LPS)-or LPS/interferon (INF)c-activated M1-like macrophages derived from human blood monocytes. In contrast, archazolid failed to elevate TNFa production from uncommitted (M0) or interleukin (IL)-4-treated M2-like macrophages. Secretion of other relevant cytokines (i.e., IL1b, IL-6, IL-10) or chemokines (i.e. IL-8 and monocyte chemotactic protein-1) from M1 was not affected by archazolid. Though V-ATPase inhibitors elevated the lysosomal pH in M1 comparable to chloroquine or ammonium chloride, the latter agents suppressed TNFa secretion. Archazolid selectively increased TNFa mRNA levels, which was abolished by dexamethasone. Interestingly, archazolid enhanced the phosphorylation and nuclear translocation of the p65 subunit of NFjB and stimulated phosphorylation of SAPK/JNK. In a microfluidically-supported human tumor biochip model, archazolid-treated M1 significantly reduced tumor cell viability. Together, our data show that V-ATPase inhibition selectively upregulates TNFa production in classically-activated macrophages along with NFjB and SAPK/JNK activation. Such increased TNFa release caused by V-ATPase inhibitors may contribute to tumor suppression in addition to direct targeting cancer cells.
Ó 2017 Elsevier Inc. All rights reserved.
Introduction
Combination of direct cytotoxic activity against tumor cells with concomitant capacity to favorably modify the tumor microenvironment might be an appealing option for pharmacological treatment of diverse cancers with clinical relevance [1] . For example, the clinically used chemotherapeutic agent trabectedin, in addition to killing cancer cells, depletes monocytes and tumor-associated macrophages (TAMs) in tumor patients as a key component of its anti-tumor activity [2] . However, the discovery of relevant targets in this respect is still in demand in order to simultaneously repress the viability of cancer cells and to modulate tumor-associated mononuclear cells by a single agent.
The vacuolar-type H(+)-ATPases (V-ATPases) are ATPdependent proton translocating macromolecular complexes that acidify lysosomes, endosomes, Golgi apparatus, and certain secretory granules in all eukaryotes [3, 4] . V-ATPases participate in physiological processes such as cellular pH homeostasis, receptor-mediated endocytosis, virus and toxin entry, intracellular trafficking as well as protein degradation and processing [3] . Aberrant regulation of pH by V-ATPases is implicated in several diseases including osteoporosis, renal tubular acidosis, and malignant neoplasms [5, 6] . V-ATPase is highly expressed on the plasma membrane of tumor cells and particularly contributes to the acidification of tumor microenvironments, thus supporting tissue damage, acquisition of metastatic cell phenotypes, and tumor invasiveness [6, 7] . Accordingly, specific inhibitors of V-ATPase that decrease the acidity of tumors, reduced the survival of tumor cells and tumor metastasis, and impaired chemoresistance [6, 8] . In fact, V-ATPase is considered as promising target in various types of cancer [6] .
Cytokines and chemokines significantly impact the tumor microenvironment to which TAMs are exposed, and represent essential factors that impact the heterogeneity of TAM functions [9] . TAMs consist of different phenotypes with partly opposite impact on tumors: the M2-like subtypes play pivotal roles in tumor progression by promoting cancer cell survival, angiogenesis, and immunosuppression, and they represent -as major part of TAMs -a remarkable fraction of tumor-infiltrating immune cells [9, 10] . In contrast, classically-activated M1-like subsets are indispensable innate immune cells with microbicidal and tumoricidal activity that produce high levels of anti-tumoral molecules such as tumor necrosis factor (TNF)a, thus opposing cancer cells and preventing the establishment and progression of cancers [1, 10] .
The role of V-ATPase in cytokine secretion was studied in peritoneal macrophages from mice or rabbits before [11] [12] [13] . Here, we aimed to obtain insights into the role of V-ATPase in cytokine and chemokine secretion from human macrophages derived from peripheral blood monocytes, taking into account macrophage plasticity and occurrence as different phenotypes. As a suitable tool to studying the role of V-ATPase we used the myxobacterial compound archazolid [14] that binds to V-ATPase [15] [16] [17] . Archazolid has been intensively investigated as anti-tumoral agent that induced apoptosis of cancer cells and reduced migration of invasive tumor cells in vitro, and decreased metastatic dissemination of breast tumors in vivo [18] [19] [20] . In various highly invasive tumor cell lines and leukemic cells, archazolid led to apoptosis due to activation of the hypoxia-inducible factor-1a (HIF1a) [18, 21] , and to anoikis induction [22] . Thus, archazolid represents a promising candidate for direct targeting of tumor cells via V-ATPase inhibition. We recently reported that archazolid reduces the secretion of cytokines and chemokines in primary human monocytes due to accumulation at the endoplasmic reticulum [23] . However, effects of archazolid on macrophages have not been addressed, and phenotype-specific functions of V-ATPase in cytokine/chemokine secretion from human macrophages have not been reported yet.
Materials and methods

Materials
Archazolid B was isolated from Archangium gephyra as previously described [14] . Apicularen A was from the natural compound library of HZI/HIPS (Braunschweig, Germany). RPMI 1640 with L-glutamine, penicillin, streptomycin, and fetal calf serum (FCS)
were from PAA Laboratories (Pasching, Germany). For in-house made ELISA, the capture and detection antibodies were from R&D Systems (Abington, UK). U0126, SB203580, nigericin, and SP600125 were from Enzo Life Sciences (Lörrach, Germany), LY294002 from BIOZOL Diagnostica Vertrieb GmbH (Eching, Germany), actinomycin D from Cayman Chemical (Ann Arbor, MI), staurosporine from Calbiochem (Merck, Darmstadt, Germany), interferon (INF)c and interleukin (IL)-4 from PeproTech (Hamburg, Germany), macrophage colony-stimulating factor (M-CSF) from Cell Guidance Systems Ltd (Cambridge, UK), Calcein-AM and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) from Thermo Fisher Scientific Inc. (Waltham, MA), LysoTracker dye from Life Technologies (Schwerte, Germany) and ammonium chloride, bafilomycin A1, chloroquine, dexamethasone, diphenyleneiodonium chloride (DPI), LPS, parthenolide, propidium iodide and all other fine chemicals were from Sigma-Aldrich (Steinheim, Germany), unless indicated otherwise.
Isolation of monocytes, differentiation to macrophages and macrophage activation
The protocols for experiments with human monocytes were approved by the ethical commission of the Friedrich-SchillerUniversity Jena. All methods were performed in accordance with the relevant guidelines and regulations. Leukocyte concentrates from peripheral blood of healthy human donors which did not take anti-inflammatory medication for the last ten days were obtained from the Institute of Transfusion Medicine, University Hospital Jena, and prepared as described [23] . Peripheral blood mononuclear cells (PBMC) were isolated by dextran sedimentation and density centrifugation on lymphocyte separation medium (LSM 1077, PAA Laboratories, Pasching, Austria). Monocytes from the PBMC fraction were isolated by adherence for 1 h at 37°C and 5% CO 2 to culture flasks (2 Â 10 7 cells/mL RPMI 1640 medium supplemented with 10% heat-inactivated FCS, 2 mM L-glutamine, 100 U/mL penicillin, and 100 mg/mL streptomycin) [24] . For differentiation towards macrophages, freshly isolated monocytes were incubated for 6 days in RPMI 1640 supplemented with 5% FCS and human recombinant M-CSF (25 ng/mL) [25] . To obtain classically-activated macrophages (M1-like), cells were further treated with 100 ng/mL LPS (designated M LPS ) or 100 ng/mL LPS plus 100 ng/mL human recombinant IFNc (M1) for 24 h. To obtain M2-like cells, macrophages were incubated with human recombinant IL-4 (20 ng/mL) for 24 h [25, 26] . To assure correct polarization, cells were assessed by flow cytometry for expression of the M2 surface markers CD163 and CD206, while M1 and M LPS were characterized by expression of CD40 and higher expression of HLA-DR (MHC class II receptor) than M2 [26] .
Determination of cell viability
The viability of human macrophages was assessed by MTT assay as described [27] . Briefly, macrophages after 6 days of differentiation of monocytes were pre-incubated with compounds for 30 min at 37°C (5% CO 2 ) and treated for 24 h with (I) 100 ng/mL LPS (M LPS ), (II) 100 ng/mL LPS plus 100 ng/mL INFc (M1), (III) 20 ng/mL IL-4 (M2) or left untreated (M0). MTT was added, cells were further incubated for 4 h, and lysed in a buffer containing 10% (w/v) SDS. Staurosporine, a pan-kinase inhibitor and inducer of apoptosis, was used as positive control. /mL) were plated into glass bottom dishes (MatTek Corporation, Ashland, MA). After adherence, cells were treated with archazolid (100 nM) or vehicle for 30 min and stimulated for 24 h with either (I) 100 ng/mL LPS, (II) 100 ng/mL LPS plus 100 ng/mL INFc, or (III) 20 ng/mL IL-4.
Immunofluorescence microscopy and live cell imaging
For imaging of fluorescein isothiocyanate (FITC) dextran (Thermo Fisher Scientific Inc.) uptake into macrophages, cells were treated as described in pH measurements. Cells were imaged immediately using the Axio Observer Z1 inverted microscope and a Plan-Apochromat 40Â/1,3 Oil DIC M27 objective or a LCI PlanNeofluar 63Â/1.3 Imm Corr DIC M27 objective.
Determination of cytokine/chemokine levels
After 6 days of differentiation of monocytes to macrophages with M-CSF (25 ng/mL) at 37°C and 5% CO 2 , test compounds or vehicle were added to macrophages and 30 min later, cells were incubated for 24 h with either (I) 100 ng/mL LPS, (II) 100 ng/mL LPS plus 100 ng/mL INFc, or (III) 20 ng/mL IL-4. For measurement of extracellular cytokine levels, supernatants were collected by centrifugation (2000g, 4°C, 10 min). Cytokines and chemokines were either analyzed by using commercially available ELISA kits (IL-8, Assaypro, St. Charles, MO) according to manufacturer's specifications, or by in-house made ELISA (IL-1b, IL-6, IL-10, TNFa, monocyte chemotactic protein (MCP)-1).
pH measurements in macrophages
pH measurements were performed according to [28] , and compositions of sodium and potassium buffers were used as described [29] . For measurements of the vesicular pH, macrophages were incubated with 0.5 mg/mL FITC-dextran (70,000 MW, SigmaAldrich) for 1 h. Cells were washed with PBS, pre-incubated with test compounds or vehicle for 30 min and stimulated with 100 ng/mL LPS for 24 h. The pH values were calculated from the ratio of fluorescence intensities excited at 480 nm and 450 nm and emission at 520 nm. In situ fluorescence calibration was performed with the ionophore nigericin (10 mM) in potassium buffer at pH values between 4.5 and 7.5.
For analysis by LysoTracker
Ò staining, macrophages (2.5 Â 10 5 /mL) were plated into glass bottom dishes (MatTek Corporation). After adherence, cells were treated with test compounds or vehicle for 30 min and stimulated with 100 ng/mL LPS for 24 h. Macrophages were then stained with the fluorescent LysoTracker Ò dye (50 nM) for 1 h. After washing, the red fluorescence of the accumulated probe in acidic cell organelles was imaged using the Axio Observer Z1 microscope and a LCI Plan-Neofluar 63x/1.3 Imm Corr DIC M27 objective.
2.7. Relative quantification of TNFa and IL-1b mRNA levels in macrophages and determination of TNFa mRNA degradation
After 6 days of differentiation of monocytes to macrophages with M-CSF (25 ng/mL), macrophages were pre-incubated with test compounds or vehicle for 30 min and stimulated with 100 ng/mL LPS for the indicated times at 37°C and 5% CO 2 . For measurement of TNFa mRNA degradation, macrophages were stimulated with 100 ng/mL LPS for 24 h and incubated with archazolid or vehicle for 1 h. Then, transcription was blocked by addition of actinomycin D (5 mg/mL) and cells were incubated for the indicated times. Total RNA was isolated using the E.Z.N.A.
Ò Total RNA Kit I (Omega Biotek, Norcross, GA) and cDNA was generated by reverse transcription with SuperScript Ò III First-Strand Synthesis SuperMix (Invitrogen). cDNA was amplified by PCR and quantified using Maxima SYBR Green/ROX qPCR Master Mix (Fermentas, Darmstadt, Germany). To calculate the relative TNFa mRNA expression (normalized to B2 M) the 2 (ÀDDC(T)) method was applied 
Determination of phosphorylation of protein kinases and transcription factors by Western blot analysis
Macrophages, obtained by differentiation of monocytes with M-CSF (25 ng/mL) at 37°C and 5% CO 2 for 6 days, were first starved for 6 h (AKT, ERK-1/2, p38 MAPK, MEK1/2, SAPK/JNK, MKK3/6) or directly pre-incubated (NFjB p65, STAT-1, STAT-3) with archazolid (100 nM) or vehicle (0.1% DMSO) for 30 min at 37°C, 5% FCS was added and cells were stimulated with LPS (100 ng/mL) for 15 min. Macrophages were placed on ice, washed once with PBS and lysed with a NP-40 lysis buffer (1% (v/v) NP-40, 1 mM sodium vanadate, 10 mM sodium fluoride, 5 mM sodium pyrophosphate, 25 mM b-glycerophosphate, 5 mM EDTA, and freshly added 10 mg/mL leupeptin hemisulfate salt, 60 mg/mL trypsin inhibitor from soybean, 1 mM phenylmethylsulfonyl fluoride in TBS, pH 7.4). Lysates were centrifuged (10,000g, 4°C, 5 min), and protein concentrations in the supernatants were determined using a Protein Assay (Bio-Rad Laboratories, Hercules, CA). After addition of 4Â SDS loading buffer (50 mM Tris-HCl, pH 6.8, 2% (w/v) SDS, 10% (v/v) glycerol, 1% (v/v) b-mercaptoethanol, 12.5 mM EDTA, 0.02% (w/v) bromophenol blue) to the lysates, samples were boiled for 5 min at 95°C. Proteins were separated by SDS-PAGE and blotted onto nitrocellulose membranes (Amersham Biosciences, Little Chalfont, UK). After blocking with 5% (w/v) bovine serum albumin or low-fat milk powder (Roth, Karlsruhe, Germany), membranes were incubated with primary antibodies overnight at 4°C. Antibodies, obtained from Cell Signaling Technology (Danvers, MA), were used as follows: NFjB p65, 1:500, rabbit monoclonal anti-NFjB p65; phospho-NFjB p65, 1:500, mouse monoclonal anti-phospho-NFjB p65; phospho-STAT-1, 1:1000, rabbit polyclonal anti-phospho-STAT-1; phospho-STAT-3, 1:1000, rabbit monoclonal anti-phospho-STAT-3; p38 MAPK, 1:1000, rabbit monoclonal anti-p38 MAPK; phospho-p38 MAPK, 1:1000, rabbit polyclonal anti-phospho-p38 MAPK; ERK-1/2, 1:1000, rabbit polyclonal anti-p44/42 ERK; phospho-ERK-1/2, 1:1000, mouse monoclonal anti-phospho-p44/42 ERK; Akt, 1:1000, mouse monoclonal anti-Akt; phospho-Akt, 1:1000, rabbit polyclonal antiphospho-Akt; MEK1/2, 1:1000, rabbit polyclonal anti-MEK1/2; phospho-MEK1/2, 1:1000, rabbit polyclonal anti-phospho-MEK1/2; phospho-MKK3, 1:1000, rabbit monoclonal antiphospho-MKK3/6; phospho-SAPK/JNK, 1:1000, mouse monoclonal anti-phospho-SAPK/JNK. Antibodies against GAPDH: 1:1000, mouse monoclonal anti-GAPDH (Santa Cruz Biotechnology, Heidelberg, Germany) and b-actin, 1:1000, mouse monoclonal antib-actin (Santa Cruz Biotechnology). Membranes were washed and incubated with fluorescently-labeled secondary antibodies (LI-COR Biosciences, Bad Homburg, Germany) for 1 h at RT in the dark. Proteins were detected using the Odyssey imaging system (LI-COR Biosciences, Bad Homburg, Germany).
Measurement of ROS formation
ROS levels were assessed as reported before [31] . Briefly, macrophages were incubated with test compounds or vehicle (0.1% DMSO) for 30 min and stimulated with LPS (100 ng/mL) for 24 h or left untreated. Cells were washed and incubated in HBSS buffer containing 2 0 -7 0 -dichlorofluorescein diacetate (DCFH-DA, Sigma-Aldrich) (10 mM) for 30 min at 37°C/5% CO 2 . To detect and quantify intracellular formation of ROS, the fluorescence of the deacetylated dye (2 0 -7 0 -dichlorofluorescein) was measured at an excitation wavelength of 485 nm and an emission wavelength of 535 nm using a NOVOstar microplate reader (BMG Labtechnologies GmbH, Offenburg, Germany).
Microfluidically supported biochip assay
Biochips were prepared by injection moulding from cyclo olefin polymer (COP) Zeonor Ò , obtained from microfluidic ChipShop GmbH (Jena, Germany), and manufactured as described previously [32] . MCF-7 cells were obtained at LGC Standards (Wesel, Germany). Authentication of MCF-7 was carried out by STR analyses (LGC Standards) and experiments were completed within 4 months of receipt of the cell line. Human umbilical vein endothelial cells (HUVEC) were isolated from human umbilical cords and cultured for up to four passages as described previously [32] . Donors were informed about the aim of the study and gave written consent. HUVEC were seeded at top of the biochip-embedded membrane, MCF-7 cells were seeded at the lower compartment of the biochip. Monocytes (in a six well plate) were differentiated towards macrophages in presence of M-CSF for 6 days, and M1 polarization was induced by addition of LPS plus IFNc while M2 polarization was induced by addition of IL-4 for 24 h. These M1 and M2 were then added to the HUVEC into the biochip. After 24 h co-culture with HUVECs, medium containing 30 nM archazolid or vehicle (0.1% DMSO) was added, and after 30 min, it was replaced by fresh medium (without archazolid). Then, cells perfused over the vascular layer with a shear stress rate of 3 dyn/cm 2 for 30 min, followed by 24 h incubation with medium.
In control experiments, macrophages were omitted and only HUVECs were used in the upper compartment. The viability of the cells was analyzed by immunofluorescence microscopy using Calcein-AM (viable cells, green) and propidium iodide (dead cells, red) staining. Mean fluorescence intensity (MFI) of the Calcein-AM staining was measured by random field analysis of 40 regions of interest per experiment.
Statistics
Data are presented as mean + standard error of the mean (SEM) of n experiments, where n represents the number of experiments. Statistical data were calculated using GraphPad InStat program (GraphPad Software, CA), and were analyzed by Student's t test for paired groups and by one-way ANOVA for independent or correlated samples followed by a Bonferroni (<5 groups) or Tukey-Kramer (>5 groups) post hoc test for multiple comparisons. A P value of <0.05 ( ⁄ ) was considered significant.
Results
Expression of V-ATPase in macrophages and effects of the V-ATPase inhibitor archazolid on the viability and morphology of macrophages
According to well-established protocols, we induced M-CSFtreated macrophages (designated M0) with LPS/INFc towards classically-activated M1 or with IL-4 towards M2-like subsets [33] . Moreover, M-CSF-treated macrophages were activated by LPS alone (designated M LPS ), which strongly resemble M1 [26] similar to macrophages activated by INFc alone [33] . Previous studies showed that macrophages from different origins and species express V-ATPase and respond to V-ATPase inhibitors in different ways [13, 31, [34] [35] [36] [37] [38] [39] . We first confirmed V-ATPase expression in human monocyte-derived macrophages [40] by Western blot (not shown) and by using immunofluorescence microscopy where no obvious differences regarding V-ATPase subcellular localization between the macrophage phenotypes were immediately apparent (Fig. 1A) . Side-by-side analysis of LAMP-1, a marker protein for lysosomes, revealed colocalisation with V-ATPase (merge, Fig. 1B) , suggesting that V-ATPase might be located to vesicles.
The V-ATPase inhibitor archazolid effectively induces apoptosis in cancer cells leading to cell death [18, 19] . Since we aimed at using arachzolid as tool compound to study V-ATPase in various human macrophage phenotypes, we first analyzed whether archazolid may affect the viability of macrophages. Incubation of activated macrophages (M LPS , M1 or M2) with archazolid (1, 10, or 100 nM) revealed no loss of cell viability within 24 h, whereas the pan-protein kinase inhibitor and apoptosis inducer staurosporine (3 mM) efficiently reduced cell viability, as expected (Fig. 1C) . Microscopic analysis confirmed cellular integrity of M LPS , M1, and M2 upon archazolid treatment but revealed obvious alterations of the cell shape for M LPS and M1 that was not evident for M2, for which the morphology was seemingly not affected by archazolid (Fig. 1D) .
V-ATPase inhibitors induce TNFa secretion in classically-activated macrophages
Having confirmed that archazolid is not detrimental for cellular integrity and viability of macrophages, we next tested whether the compound could modulate cytokine and chemokine release. Differentiated macrophages (M0) were pretreated with archazolid and then either activated by LPS/INFc (M1) or IL-4 (M2) for 24 h. Analysis of IL-1b, IL-6, IL-8, IL-10 and MCP-1 in the medium revealed no significant modulation of the release of these proteins by archazolid neither in M1 nor in M2 (Fig. 2A) . However, the levels of TNFa were upregulated by archazolid (100 nM) about 2.4-fold in M1, whereas the compound failed to alter TNFa levels in M2 ( Fig. 2A ) and in M0 (not shown). More detailed concentration response experiments showed that for M LPS or M1 the maximal effect (2.9-to 3.4-fold) on TNFa release was obtained at 30 nM archazolid and slightly declined at 100 nM (Fig. 2B) . In contrast to archazolid and as expected, dexamethasone repressed TNFa levels in M LPS and M1 (Fig. 2B) . To confirm that the observed effect of archazolid is related to interference with V-ATPase, we tested other V-ATPase inhibitors, that is, apicularen A and bafilomycin A1 (1, 10 and 100 nM, each) in the same experimental settings. For both compounds upregulation of TNFa levels was evident in M LPS and M1 with maximal effects at 10 nM (Fig. 2C) , supporting that suppression of V-ATPase accounts for increased TNFa release. from human blood monocytes after differentiation with M-CSF (25 ng/mL) for six days, were stimulated with LPS (100 ng/mL), with LPS (100 ng/mL) plus IFNc (100 ng/mL) or with IL-4 (20 ng/mL) for 24 h. Cells were permeabilized and incubated with an antibody against V-ATPase (green), followed by Alexa Fluor 488 goat anti-rabbit IgG. Nuclei were stained with DAPI (blue). (B) Macrophages were stimulated with LPS (100 ng/mL) plus IFNy (100 ng/mL) for 24 h, permeabilized and incubated with antibodies against v-ATPase (green) or LAMP-1 (red), followed by Alexa Fluor 488 goat anti-rabbit IgG and Alexa Fluor 555 goat anti-rabbit IgG; nuclei were stained with DAPI (blue); differential interference contrast. (C, D) Macrophages were pre-incubated with archazolid (1, 10, 100 nM (C) and 100 nM (D)), staurosporine (3 mM) or vehicle (0.1% DMSO) for 30 min and stimulated with LPS (100 ng/mL), with LPS (100 ng/mL) plus IFNc (100 ng/mL) or with IL-4 (20 ng/mL) for 24 h. 
Archazolid causes elevation of the lysosomal pH in classicallyactivated macrophages
Blocking V-ATPase is well-known to cause an elevated lysosomal pH in various cell types [16, 41, 42] , and along these lines, archazolid led to significantly increased lysosomal pH in M LPS as evidenced by the pH-dependent internalization of FITC-labeled dextran (Fig. 3A) . Elevation of the lysosomal pH by archazolid was pronounced at 100 nM but only slightly affected at 10 nM. In agreement with the literature [43, 44] , chloroquine (100 mM) and NH 4 Cl (50 mM), used as control tools, elevated the lysosomal pH in M LPS to a comparable degree as 10 nM archazolid (Fig. 3A) . A similar result was obtained, when changes of pH in organelles were monitored using the pH sensitive LysoTracker Ò probe and fluorescence microscopy (Fig. 3B) . Note that the structurally distinct V-ATPase inhibitor apicularen A also elevated the pH in organelles of M LPS , just like archazolid. In order to investigate whether the increased release of TNFa by archazolid and other V-ATPase inhibitors was due to lysosomal pH alterations, we took advantage of chloroquine and NH 4 Cl as tool compounds (that also elevated the lysosomal pH) and tested if these agents could increase TNFa release from M LPS and M1 as well. Surprisingly, chloroquine (100 mM) and NH 4 Cl (50 mM) failed to enhance TNFa release, but instead markedly repressed it in both M LPS and M1 (Fig. 3C) . Therefore, the data suggest that other mechanisms than solely elevation of lysosomal pH is responsible for the TNFa-upregulatory effects by archazolid and other V-ATPase inhibitors.
Archazolid affects TNFa release on the mRNA level and increases TNFa mRNA expression in classically-activated macrophages
The stimulatory effect of archazolid on TNFa release in classically-activated M1 was abrogated by co-incubation with dexamethasone (Fig. 4A) , a glucocorticoid that interferes with TNFa gene expression. This finding led us to assume that archazolid may affect the expression of TNFa at the mRNA level. M(0) were pretreated with or without archazolid in the presence or absence of dexamethasone and 30 min later, LPS was added to obtain M LPS . TNFa mRNA levels after 4 and 8 h were significantly higher in the presence of archazolid versus cells treated with LPS alone, and also after 1 and after 16, 20 and 24 h, archazolid led to elevated levels of TNF mRNA (Fig. 4B) . Note that mRNA of IL-1b, studied as control, was not increased by archazolid (Fig. 4B) . Coincubation with dexamethasone effectively repressed the up-regulatory effect of a g Fig. 3 . Effects of V-ATPase inhibition on the lysosomal pH of human macrophages and correlation with cytokine release. Human isolated blood monocytes were differentiated to macrophages with M-CSF (25 ng/mL) within six days. (A) Macrophages were incubated with FITC-dextran (0.5 mg/mL) for 60 min, preincubated with archazolid at the indicated concentrations, ammonium chloride (50 mM), chloroquine (100 mM), or vehicle (0.1% DMSO) for 30 min and stimulated with LPS (100 ng/mL) for 24 h. FITC-Dextran uptake into lysosomes was determined by measurement of emission at 520 nm or by analysis of immunofluorescence pictures (FITC-dextran: green; differential interference contrast). (B) Macrophages were pre-incubated with archazolid (100 nM), apicularen A (100 nM), ammonium chloride (50 mM) or vehicle (DMSO) for 30 min and stimulated with LPS (100 ng/mL) for 24 h. Macrophages were incubated with LysoTracker (50 nM; red) for 60 min and staining of acidic organelles was observed using a fluorescence microscope. (C) Macrophages were pre-incubated with archazolid (10 nM), ammonium chloride (50 mM), chloroquine (100 mM) or vehicle (DMSO) for 30 min and stimulated with LPS (100 ng/mL) or LPS (100 ng/mL) plus IFNc (100 ng/mL) for 24 h. TNFa levels in supernatants were analyzed by ELISA. Values are given as percentage of vehicle control (=100%), means + SEM; n = 8 (A, left panel), n = 3 (C). archazolid on TNFa mRNA expression (Fig. 4B) . Experiments using actinomycin D that blocks mRNA transcription showed that archazolid does not affect TNFa mRNA degradation as possible reason for elevation of mRNA levels (Fig. 4C ).
Effects of archazolid on protein kinases and transcription factors involved in LPS-signaling and on ROS formation
Because archazolid seemingly enhances the LPS-induced expression of TNFa mRNA in M LPS , it appeared possible that the compound modulates LPS-induced signal transduction pathways. We thus analyzed the phosphorylation of typical protein kinases (PK) that are integrated in LPS-induced TNFa expression. M(0) were pre-treated with archazolid or respective reference PK inhibitors, stimulated with LPS for 15 min and analyzed for the phosphorylated form of the kinases by Western blot. LPS caused phosphorylation of Akt, ERK-1/2, p38 MAPK, MEK-1/2, and MEK-3/6 (Fig. 5A ) but archazolid (10 or 100 nM) failed to modulate their phosphorylation. The reference inhibitors LY294002 for Akt phosphorylation, U0126 for ERK, and SB203580 for p38 MAPK, used to validate the identity of respective phosphorylated kinases/ proteins detected by Western blot, blocked LPS-induced phosphorylation, as expected (Fig. 5A) . A tendency for stimulated SAPK/JNK phosphorylation (reference inhibitor SP600125) was observed for 10 and 100 nM archazolid, although statistical significance was not reached (Fig. 5A) . However, archazolid (10 and 100 nM) clearly elevated the phosphorylation of the p65 subunit of the transcription factor NFjB in M LPS without marked elevation of NFjB p65 expression (Fig. 5B ). An NFjB-stimulatory effect of archazolid was also observed when the translocation of activated NFjB to the nucleus was monitored using immunofluorescence microscopy, in agreement with disappearance of the NFjB chaperon IjB (Fig. 5C) . Note that the LPS-induced phosphorylation of other relevant transcription factors, that is, STAT-1 and STAT-3 in M1 was not elevated by archazolid (Fig. 5D) .
Because ROS production is closely linked to NFjB and SAPK/JNK signaling [45] , we investigated if archazolid could modulate LPSinduced ROS formation in macrophages. Pre-incubation of macrophages with 10 or 30 nM archazolid prior to LPS significantly increased ROS levels within 24 h whereas the NADPH oxidase inhibitor DPI diminished ROS formation induced by LPS, as expected, and also abrogated the elevated ROS levels caused by archazolid (Fig. 6A) . Finally, we investigated if the elevated ROS and NFjB activation are involved in archazolid-induced TNFa release. In fact, DPI (5 mM) that reduced archazolid-elicited ROS formation as well as the NFjB activation inhibitor parthenolide (10 mM) efficiently prevented the stimulatory effects of archazolid plus LPS on TNFa release from macrophages (Fig. 6B ).
Archazolid enhances M1-mediated cytotoxicity against MCF-7 cells in a microfluidically biochip assay
To investigate if treatment of macrophages by archazolid influences cancer cell viability in co-cultures, we utilized a microfluidically-supported biochip assay [32] , designed as a dynamically perfused three-dimensional human tumor model (Fig. 7A) . Macrophages, polarized towards M1 or M2 were added to endothelial cells (ECs) and co-cultured in the upper chamber. The ECs are thought to separate the tumor from the blood cells mimicking the physiological barrier. MCF-7 cells, resembling the tumor component, were cultured underneath the EC-macrophage cell layer. EC-macrophage cell layers treated with archazolid (30 nM) for 30 min and subsequent incubation for 24 h significantly reduced the viability of MCF-7 cells in models containing M1, whereas in models containing M2 or in models devoid of macrophages, archazolid failed in this respect (Fig. 7B, C) .
Discussion
Here we show that pharmacological targeting of V-ATPase causes selective elevation of TNFa production in classicallyactivated (i.e., M1 and M LPS ) human macrophage phenotypes. Intriguingly, the concomitant release of other cytokines (i.e. IL1b, IL-6, IL-10) or chemokines (i.e. IL-8, MCP-1) in M1 and M LPS was not elevated, and the corresponding cytokine/chemokine secretion of uncommitted M(0) and of alternatively activated M2 was not affected by archazolid. Because also other V-ATPase inhibitors such as bafilomycin and apicularen led to comparable effects, we suggest that interference with V-ATPase but not with an off-target of archazolid [46] is causative for the elevated TNFa levels. It appears that V-ATPase inhibition enhances the LPS-or LPS/INFc-induced response of macrophages for TNFa expression, seemingly by augmenting LPS-evoked NFjB activation and ROS formation. Finally, in a biochip tumor model, archazolid caused reduced viability of MCF-7 breast cancer cells in co-culture with M1, but not with M2 or in absence of macrophages. Our data suggest that V-ATPase in classically-activated macrophages may play a regulatory role in TNFa expression implying a therapeutic potential for V-ATPase inhibitors to intervene with diseases where increased TNFa levels might be beneficial, such as cancer.
V-ATPase is ubiquitously expressed in mammals and was studied in macrophages before, where it was shown to play roles in lysosomal and cytoplasmic pH homeostasis [34, 42, 47, 48] . Also in our study, using archazolid for the first time as tool for investigating V-ATPase functions in macrophages, modulation of lysosomal pH homeostasis was apparent, since archazolid caused elevation of the pH in lysosomes. Of interest, in contrast to cancer cells that overexpress V-ATPase [5, 6] and where V-ATPase inhibition by archazolid induces cell death [18] [19] [20] 22, 49] , the viability of human monocyte-derived macrophages was not impaired in response to V-ATPase interference by archazolid. Similarly, archazolid failed to reduce the viability of human primary monocytes [23] .
Pharmacological manipulation of V-ATPase in macrophages by respective inhibitors such as bafilomycin A1 was reported before [13, 31, 35, 37, 38, 48, 50] . Many of these studies focused on osteoclasts [51] , macrophage cell lines [31] and macrophages from rodents [37, 39, 48] and from other animals [52] , but only few studies addressed V-ATPase functions in human primary macrophages [40, 50] , and to the best of our knowledge there are no reports that studied the role of V-ATPase on cytokine/chemokine secretion of different macrophage phenotypes, such as M1 and M2. Therefore, one significant novelty of our study is the consideration of distinct human macrophage subtypes, that is, uncommitted M(0), classically-activated M1-like and so-called ''resolving" M2-like macrophages that significantly differ in their bioactions [53] . In fact, we show here that blocking V-ATPase upregulates TNFa expression in classically-activated M1-like but not so in M(0) and M2 subtypes.
A previous study demonstrated that bafilomycin A1 reduced the amount of TNFa in LPS-activated alveolar macrophages from rabbits [11] , and we recently found that archazolid suppresses TNFa secretion from human monocytes [23] . These opposing results versus our present data emphasize the need of distinguishing between monocyte/macrophage subsets. Recently, a differential role of V-ATPase in M1 and M2 was observed in phagosome pH regulation [40] . In line with our data are previous findings showing that V-ATPase suppresses NFjB and cytokine expression in LPS-or INFc-activated macrophages [12] . It is noteworthy that among various cytokines and chemokines, solely TNFa was affected by archazolid. The reason for this effect is unknown but selective elevation of TNFa without concomitant increase of Il-1b via NFjB was also observed in LPS-stimulated murine peritoneal macrophages treated with the protein biosynthesis inhibitor cycloheximide [54] . Of interest, V-ATPase might be of importance for polarization towards M2 subsets. Thus, the lysosomal adaptor protein Lamtor1, which forms an amino-acid sensing complex with V-ATPase, was recently shown to be required for M2 polarization [55] . Moreover, V-ATPase was reported to modulate macrophage polarization in tumor-bearing mice [56] , and inhibition of the V-ATPase a2 isoform in murine tumor cells delayed tumor growth by decreasing M2-like TAMs in the tumor microenvironment [57] .
In our study, targeting of V-ATPase in classically-activated macrophages caused marked elevation of lysosomal pH, a typical effect of V-ATPase inhibitors that block the proton-pumping activity of V-ATPase [16, 41, 42] . Therefore, it appeared possible that lysosomal pH elevation is causative for increased TNFa expression. However, the control tool compounds chloroquine and NH 4 Cl that are known to increase lysosomal pH in macrophages [43, 44] , also elevated the pH in lysosomes of M LPS comparable as archazolid, but TNFa release was not increased but rather impaired. These data suggest that simply elevation of lysosomal pH is probably not the cause for increased TNFa expression by targeting V-ATPase.
Our detailed analysis of PKs and transcription factors that are potentially involved in induction of TNFa expression [58] excluded the MEK1/2 -ERK, MEK3/6 -p38 MAPK, and Akt pathway as well as STAT-1 and -3 as signaling molecules since archazolid treatment of M LPS did not increase phosphorylation/activation of these proteins. Instead, phosphorylation of the p65 subunit of NFjB and the nuclear translocation of NFjB p65 were markedly promoted by archazolid, along with almost complete disappearance of the NFjB chaperon IjB. Since NFjB regulates TNFa expression in macrophages at the transcriptional level [59, 60] , we concluded that interference with V-ATPase by archazolid leads to elevation of TNFa mRNA expression. This is supported by the finding that the glucocorticoid dexamethasone which diminishes NFjB levels [59] , completely prevented archazolid-induced TNFa mRNA levels. Note that besides NFjB also the SAPK/JNK was slightly activated by archazolid, a signaling molecule controlling TNFa translation in macrophages susceptible to dexamethasone [61] . Based on our experiments with actinomycin D the stability of TNFa mRNA was not affected by archazolid. Although TNFa is well known to augment NFjB signaling [62] , it is unlikely that archazolid-induced TNFa is causative for increased NFjB activation, as the later was elevated already 15 min upon exposure to archazolid while TNFa induction was delayed up to hours. Macrophages substantially produce ROS during bacterial killing to clear infections. In agreement with increased ROS formation in murine macrophages exposed to the V-ATPase inhibitors bafilomycin A1 or to concanamycin A [31] , archazolid enhanced LPS-induced ROS formation in human macrophages, which was sensitive to the NDAPH oxidase inhibitor DPI. Of interest, DPI also blocked archazolid-induced TNFa release implying a requirement of ROS in this respect. In fact, ROS production was shown to be closely linked to NFjB and SAPK/JNK activity [45] .
In summary, we showed that pharmacological targeting of V-ATPase has phenotype-specific consequences for human macrophage functions. Substantial secretion of TNFa is a hallmark of activated macrophages which is increased by V-ATPase inhibition. Although TNFa is a potent pro-inflammatory cytokine that contributes to excessive and unresolved inflammation, controlled temporal and spatial elevation of TNFa may be beneficial in cancer treatment. In fact, attempts have been made to stimulate macrophages for higher TNFa production, for example by TLR-9 activators and CpG oligodeoxynucleotides [63, 64] in order to promote immune reactions against the tumor. Our results from the biochip tumor model support anti-tumoral properties of archazolid in combination with M1 but not with M2. Together, V-ATPase inhibitors may have the appeal to act at least in two ways that could synergize in cancer therapy: (i) direct anti-tumoral effects against susceptible cancer cells and (ii) beneficial impact against tumors by phenotype-specific manipulation of macrophages in the tumor microenvironment.
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